U.S. Healthcare Data Monetization Market (2026 - 2033) For Quality, Outcomes & Payment Intelligence Size, Share & Trends Analysis Report By Entity (Healthcare Entities, Non-healthcare Entities), By Product Type (Data Subscription), By Buyer, By Buyer Vs Product Type, And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                    1.2. Market Definitions
                    1.3. Information Procurement
                        1.3.1. Purchased Database
                        1.3.2. GVR’s Internal Database
                        1.3.3. Secondary Sources & Third-Party Perspectives
                        1.3.4. Primary Research
                        1.3.5. Details of Primary Research
                    1.4. Information Analysis
                        1.4.1. Data Analysis Models
                    1.5. Methodology Architecture Overview
                        1.5.1. Modeling framework
                            1.5.1.1. Serviceable Obtainable Market (SOM) Analysis - Approach/Assumptions
                                1.5.1.1.1. Commodity Flow Analysis
                                1.5.1.1.2. Scenario-Based Penetration Modeling (2021 - 2033)
                                1.5.1.1.3. Interpretation of the Penetration Model
                            1.5.1.2. Total Addressable Market (TAM) Analysis - Approach/Assumptions
                                1.5.1.2.1. Bottom-up estimation logic
                                1.5.1.2.2. Top-down validation logic
                                1.5.1.2.3. Triangulation framework
                            1.5.1.3. QFD-Based Methodology for SOM Share Allocation
                                1.5.1.3.1. Scenario-based SOM share allocation
                    1.6. List of Secondary Sources
                    1.7. List of Primary Sources
Chapter 2. Executive Summary
                    2.1. Market attractiveness snapshot
                    2.2. Segment Snapshot
                    2.3. Competitive Landscape Snapshot
                    2.4. Top 3 monetization pathways
                    2.5. Priority use cases
                    2.6. Key risks (regulatory + channel conflict)
Chapter 3. Market Variables, Trends, and Scope
                    3.1. U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Market - Market Dynamics
                        3.1.1. Market Driver Analysis
                        3.1.2. Market Restraint Analysis
                        3.1.3. Market Opportunity Analysis
                        3.1.4. Market Challenge Analysis
                    3.2. Business Environmental Tools Analysis: U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Market
                        3.2.1. Porter’s Five Forces Analysis
                            3.2.1.1. Supplier power
                            3.2.1.2. Buyer power
                            3.2.1.3. Substitution threat
                            3.2.1.4. Threat of new entrant
                            3.2.1.5. Competitive rivalry
                        3.2.2. PESTLE Analysis
                            3.2.2.1. Political landscape
                            3.2.2.2. Economic and Social landscape
                            3.2.2.3. Technological landscape
                            3.2.2.4. Environmental landscape
                            3.2.2.5. Legal Landscape
Chapter 4. U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: By Entity TAM, SAM & SOM Estimates & Trend Analysis
                    4.1. U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Entity: Key Takeaways
                    4.2. U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Market: Entity Movement & Market Share Analysis, 2025 & 2033
                    4.3. Healthcare entities
                        4.3.1. TAM, SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                        4.3.2. Product Type
                            4.3.2.1. Data Subscription (patient-level / aggregate / licensed datasets)
                                4.3.2.1.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                            4.3.2.2. Insights-as-a-Service (curated analytics products)
                                4.3.2.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                            4.3.2.3. Models / Decision Engines (AI-enabled predictive products)
                                4.3.2.3.1. TAM, SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                        4.3.3. Buyer Type
                            4.3.3.1. Pharmaceutical Companies
                                4.3.3.1.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                                4.3.3.1.2. Clinical Trial Enablement (Site selection, patient identification, feasibility analytics)
                                    4.3.3.1.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                                4.3.3.1.3. HCP & Customer Targeting (Physician targeting, segmentation, sales enablement)
                                    4.3.3.1.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                                4.3.3.1.4. Safety, Adherence & HEOR (RWE, adherence analytics, pharmacovigilance, outcomes tracking)
                                    4.3.3.1.4.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                                4.3.3.1.5. Formulary Analytics / Commercial Access Enablement (Market access, payer strategy, reimbursement analytics)
                                    4.3.3.1.5.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                            4.3.3.2. Health Systems & Providers
                                4.3.3.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                                4.3.3.2.2. Go-to-Market & Contracting (Value-based care enablement, service line optimization)
                                    4.3.3.2.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                                4.3.3.2.3. Quality & Care Gap Closure (HEDIS, Stars, performance improvement)
                                    4.3.3.2.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                                4.3.3.2.4. Network & Operational Optimization (Referral management, capacity optimization, leakage reduction)
                                    4.3.3.2.4.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                                4.3.3.2.5. Formulary Analytics / Commercial Access Enablement (Market access, payer strategy, reimbursement analytics)
                                    4.3.3.2.5.1. TAM, SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                            4.3.3.3. Retail Pharmacies
                                4.3.3.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                                4.3.3.3.2. Independent Pharmacies
                                    4.3.3.3.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                                4.3.3.3.3. Chain Pharmacies
                                    4.3.3.3.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                            4.3.3.4. Other Non-Payer Healthcare Entities
                                4.3.3.4.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                    4.4. Non-healthcare entities
                        4.4.1. TAM, SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Buyer vs Product Type Sub-Segmentation SAM & SOM Estimates & Trend Analysis
                    5.1. U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Buyer vs Sub-Segmentation: Key Takeaways
                    5.2. U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Market: Buyer × Sub-Segmentation Movement & Market Share Analysis, 2025 & 2033
                    5.3. Pharmaceutical Companies
                        5.3.1. Clinical Trial Enablement (Site selection, patient identification, feasibility analytics)
                            5.3.1.1. Data subscription (clinical + claims + quality datasets)
                                5.3.1.1.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                            5.3.1.2. Insights service (trial feasibility analytics)
                                5.3.1.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                            5.3.1.3. Model/engines (site selection AI tools)
                                5.3.1.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                        5.3.2. Health Systems & Providers
                            5.3.2.1. Data (HCP-level claims + quality signals)
                                5.3.2.1.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                            5.3.2.2. Insights (targeting analytics)
                                5.3.2.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                            5.3.2.3. Models (real-time targeting engines)
                                5.3.2.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                        5.3.3. Safety, Adherence & HEOR (RWE, adherence analytics, pharmacovigilance, outcomes tracking)
                            5.3.3.1. Data (payer + quality + reimbursement datasets)
                                5.3.3.1.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                            5.3.3.2. Insights (access analytics)
                                5.3.3.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                            5.3.3.3. Models (pricing / access optimization tools)
                                5.3.3.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                        5.3.4. Formulary Analytics/Commercial Access Enablement (Market access, payer strategy, reimbursement analytics)
                            5.3.4.1. Data (payer + quality + reimbursement datasets)
                                5.3.4.1.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                            5.3.4.2. Insights (access analytics)
                                5.3.4.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                            5.3.4.3. Models (pricing / access optimization tools)
                                5.3.4.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                    5.4. Health Systems & Providers
                        5.4.1. Data (EMR + claims + quality data)
                            5.4.1.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                        5.4.2. Insights (care gap + operational analytics)
                            5.4.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                        5.4.3. Models (VBC optimization engines)
                            5.4.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                    5.5. Retail Pharmacies
                        5.5.1. Data (patient + prescription + adherence signals)
                            5.5.1.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                        5.5.2. Insights (patient behavior / refill optimization)
                            5.5.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                        5.5.3. Models (adherence / engagement engines)
                            5.5.3.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                    5.6. Other Non-Payer Healthcare Entities
                        5.6.1. Data packages
                            5.6.1.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                        5.6.2. Insights platforms
                            5.6.2.1. SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
                        5.6.3. API/embedded models
                            5.6.3.1. TAM, SAM & SOM Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Pricing Benchmarks and ACV Ranges (2025)
                    6.1. Buyer × Product Type ACV Benchmarks
                        6.1.1. Pharmaceutical Companies
                            6.1.1.1. Clinical Trial Enablement
                                6.1.1.1.1. Data subscription (clinical + claims + quality datasets)
                                6.1.1.1.2. Insights service (trial feasibility analytics)
                                6.1.1.1.3. Model/engines (site selection AI tools)
                            6.1.1.2. Health Systems & Providers
                                6.1.1.2.1. Data (HCP-level claims + quality signals)
                                6.1.1.2.2. Insights (targeting analytics)
                                6.1.1.2.3. Models (real-time targeting engines)
                            6.1.1.3. Safety, Adherence & HEOR
                                6.1.1.3.1. Data (payer + quality + reimbursement datasets)
                                6.1.1.3.2. Insights (access analytics)
                                6.1.1.3.3. Models (pricing / access optimization tools)
                            6.1.1.4. Formulary Analytics/Commercial Access Enablement
                                6.1.1.4.1. Data (payer + quality + reimbursement datasets)
                                6.1.1.4.2. Insights (access analytics)
                                6.1.1.4.3. Models (pricing / access optimization tools)
                        6.1.2. Health Systems & Providers
                            6.1.2.1. Data (EMR + claims + quality data)
                            6.1.2.2. Insights (care gap + operational analytics)
                            6.1.2.3. Models (VBC optimization engines)
                        6.1.3. Retail Pharmacies
                            6.1.3.1. Data (patient + prescription + adherence signals)
                            6.1.3.2. Insights (patient behavior / refill optimization)
                            6.1.3.3. Models (adherence / engagement engines)
                        6.1.4. Other Non-Payer Healthcare Entities
                            6.1.4.1. Data packages
                            6.1.4.2. Insights platforms
                            6.1.4.3. API / embedded models
                    6.2. By Contract Structure
                        6.2.1. Annual license
                        6.2.2. Per-query / API-based
                        6.2.3. Subscription vs bulk licensing
                    6.3. Cross-Cutting Pricing Questions & Premium Drivers
Chapter 7. U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Buyer Demand & WTP Ranking
                    7.1. Ranking by Buyer & Product Type Segment
                        7.1.1. Willingness to Pay (WTP) Analysis Anchors
                    7.2. Observable Demand Signals
                        7.2.1. Published or disclosed contract values
                        7.2.2. Request for proposal (RFP) trends
                        7.2.3. Transaction comps for comparable payer-adjacent data assets
                    7.3. Adoption Benchmarks
                        7.3.1. Average sales cycle length by buyer segment
                        7.3.2. Time-to-first-deal for comparable new entrants
                        7.3.3. Product-type adoption rates
Chapter 8. Competitive Landscape
                    8.1. Company Categorization
                    8.2. Company Profiles/Listing
                        8.2.1. Arcadia Solutions, LLC
                            8.2.1.1. Overview
                            8.2.1.2. Financial Performance
                            8.2.1.3. Product Benchmarking
                            8.2.1.4. Strategic Initiatives
                        8.2.2. Inovalon
                            8.2.2.1. Overview
                            8.2.2.2. Financial Performance
                            8.2.2.3. Product Benchmarking
                            8.2.2.4. Strategic Initiatives
                        8.2.3. IQVIA
                            8.2.3.1. Overview
                            8.2.3.2. Financial Performance
                            8.2.3.3. Product Benchmarking
                            8.2.3.4. Strategic Initiatives
                        8.2.4. Optum, Inc.
                            8.2.4.1. Overview
                            8.2.4.2. Financial Performance
                            8.2.4.3. Product Benchmarking
                            8.2.4.4. Strategic Initiatives
                        8.2.5. Komodo Health, Inc.
                            8.2.5.1. Overview
                            8.2.5.2. Financial Performance
                            8.2.5.3. Product Benchmarking
                            8.2.5.4. Strategic Initiatives
                        8.2.6. Cotiviti, Inc.
                            8.2.6.1. Overview
                            8.2.6.2. Financial Performance
                            8.2.6.3. Product Benchmarking
                            8.2.6.4. Strategic Initiatives
                        8.2.7. Symphony Health
                            8.2.7.1. Overview
                            8.2.7.2. Financial Performance
                            8.2.7.3. Product Benchmarking
                            8.2.7.4. Strategic Initiatives
                        8.2.8. Definitive Healthcare
                            8.2.8.1. Overview
                            8.2.8.2. Financial Performance
                            8.2.8.3. Product Benchmarking
                            8.2.8.4. Strategic Initiatives
                        8.2.9. Truveta
                            8.2.9.1. Overview
                            8.2.9.2. Financial Performance
                            8.2.9.3. Product Benchmarking
                            8.2.9.4. Strategic Initiatives
                    8.3. Monetization Models Overview
                            8.3.1.1. Assessment across data, insights, and model-driven offerings
                            8.3.1.2. Directional view of pricing approaches and commercialization model
                            8.3.1.3. Pricing Mechanism Taxonomy
                            8.3.1.4. Company-Level Commercialization Model Summary
                            8.3.1.5. Directional ACV Benchmarking Summary
                            8.3.1.6. Key Commercial Dynamics & Implications

List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence, by entity, 2021 - 2033 (USD Million)
Table 4 U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence, by product type, 2021 - 2033 (USD Million)
Table 5 U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence, by buyer type, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot, 2025 (USD Million)
Fig. 9 Market segmentation insights
Fig. 10 Competitive landscape
Fig. 11 Market driver impact
Fig. 12 Market restraint impact
Fig. 13 Porter’s analysis
Fig. 14 PESTLE analysis
Fig. 15 U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Total Addressable Market (TAM) outlook and key takeaways
Fig. 16 U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Entity movement analysis
Fig. 17 Healthcare entities market, 2021 - 2033 (USD Million)
Fig. 18 Non-healthcare entities market, 2021 - 2033 (USD Million)
Fig. 19 U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Serviceable Available Market (SAM) outlook and key takeaways
Fig. 20 U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Entity movement analysis
Fig. 21 Healthcare entities market, 2021 - 2033 (USD Million)
Fig. 22 Non-healthcare entities market, 2021 - 2033 (USD Million)
Fig. 23 U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Serviceable Obtainable Market (SOM) outlook and key takeaways
Fig. 24 U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Entity movement analysis
Fig. 25 Healthcare entities market, 2021 - 2033 (USD Million)
Fig. 26 Non-healthcare entities market, 2021 - 2033 (USD Million)
Fig. 27 U.S. Healthcare Data Monetization Market for Quality, Outcomes & Payment Intelligence: Entity movement analysis
Fig. 28 U.S. Healthcare Entities Market, by Product Type, Serviceable Available Market (SAM), 2021 - 2033 (USD Million)
Fig. 29 U.S. Healthcare Entities Market, by Buyer Type, Serviceable Available Market (SAM), 2021 - 2033 (USD Million)
Fig. 30 U.S. Healthcare Entities Market, by Pharmaceutical Companies, Serviceable Available Market (SAM), 2021 - 2033 (USD Million)
Fig. 31 U.S. Healthcare Entities Market, by Health Systems & Providers, Serviceable Available Market (SAM), 2021 - 2033 (USD Million)
Fig. 32 U.S. Healthcare Entities Market, by Retail Pharmacies, Serviceable Available Market (SAM), 2021 - 2033 (USD Million)
Fig. 33 U.S. Healthcare Entities Market, by Product Type, Serviceable Obtainable Market (SOM), 2021 - 2033 (USD Million)
Fig. 34 U.S. Healthcare Entities Market, by Buyer, Serviceable Obtainable Market (SOM), 2021 - 2033 (USD Million)
Fig. 35 U.S. Healthcare Entities Market, by Pharmaceutical Companies, Serviceable Obtainable Market (SOM), 2021 - 2033 (USD Million)
Fig. 36 U.S. Healthcare Entities Market, by Health Systems & Providers, Serviceable Obtainable Market (SOM), 2021 - 2033 (USD Million)
Fig. 37 U.S. Healthcare Entities Market, by Retail Pharmacies, Serviceable Obtainable Market (SOM), 2021 - 2033 (USD Million)
Fig. 38 U.S. Pharmaceutical Companies, by Clinical Trial Enablement, Serviceable Available Market (SAM), 2021 - 2033 (USD Million)
Fig. 39 U.S. Pharmaceutical Companies, by HCP & Customer Targeting, Serviceable Available Market (SAM), 2021 - 2033 (USD Million)
Fig. 40 U.S. Pharmaceutical Companies, by Safety, Adherence & HEOR, Serviceable Available Market (SAM), 2021 - 2033 (USD Million)
Fig. 41 U.S. Pharmaceutical Companies, by Formulary Analytics/Commercial Access Enablement, Serviceable Available Market (SAM), 2021 - 2033 (USD Million)
Fig. 42 U.S. Health Systems & Providers, Product Type, Serviceable Available Market (SAM), 2021 - 2033 (USD Million)
Fig. 43 U.S. Retail Pharmacies, Product Type, Serviceable Available Market (SAM), 2021 - 2033 (USD Million)
Fig. 44 U.S. Other Non-Payer Healthcare Entities, Product Type, Serviceable Available Market (SAM), 2021 - 2033 (USD Million)
Fig. 45 U.S. Pharmaceutical Companies, by Clinical Trial Enablement, Serviceable Obtainable Market (SOM), 2021 - 2033 (USD Million)
Fig. 46 U.S. Pharmaceutical Companies, by HCP & Customer Targeting, Serviceable Obtainable Market (SOM), 2021 - 2033 (USD Million)
Fig. 47 U.S. Pharmaceutical Companies, by Safety, Adherence & HEOR, Serviceable Obtainable Market (SOM), 2021 - 2033 (USD Million)
Fig. 48 U.S. Pharmaceutical Companies, by Formulary Analytics/Commercial Access Enablement, Serviceable Obtainable Market (SOM), 2021 - 2033 (USD Million)
Fig. 49 U.S. Health Systems & Providers, Product Type, Serviceable Obtainable Market (SOM), 2021 - 2033 (USD Million)
Fig. 50 U.S. Retail Pharmacies, Product Type, Serviceable Obtainable Market (SOM), 2021 - 2033 (USD Million)
Fig. 51 U.S. Other Non-Payer Healthcare Entities, Product Type, Serviceable Obtainable Market (SOM), 2021 - 2033 (USD Million)